Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
TauRx Grosses $119m From Warrant Exercise
Executive Summary
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
You may also be interested in...
Building On Successes During Turbulent Times, SR One Closes $600m Fund II
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Roche Buys IL-2 Technology From Good, Which Forms New Firm Bonum
Roche is paying $250m up front to buy Good Therapeutics, which will launch a new company, Bonum Therapeutics, to explore its platform technology for targets other than interleukin-2.